Home Aletta®

Discover how Aletta® sets a new standard for blood collection

Aletta®, the world’s first Autonomous Robotic Phlebotomy Device™ (ARPD™), automates the diagnostic blood collection process.

Patient punctured by Aletta

Addresses staffing shortages

Aletta® is designed to reduce workload, improve efficiency, and enhance the patient experience.

Performs a fully autonomous blood draw

Aletta® performs the entire blood draw on its own, from placing the tourniquet to applying the bandage.

Supports large-volume sites

In our model, one supervisor can oversee up to three Aletta® devices, making it ideal for busy blood draw centers.

Automating phlebotomy with Aletta® ARPD™

Aletta® is designed to automate routine blood draws to reduce errors and ensure consistency.
Aletta® aims to improve the patient experience by offering smoother blood draws and shorter wait times.
In our vision, one trained phlebotomist can oversee up to three Aletta® devices, allowing phlebotomy departments to work manage staffing challenges.

Aletta® is designed to perform the complete blood draw procedure autonomously. This includes identification of a suitable vein, inserting the needle, changing and inverting the tubes, and placing the bandage.

To locate a suitable vein, Aletta® uses multimodal imaging that combines near infrared and ultrasound. In addition, the device uses Doppler ultrasound to confirm it has selected a vein and not an artery. Then, Aletta® positions and inserts the needle with submillimeter precision.

By automating these steps, Aletta® aims to improve consistency and reduce variability in blood collection. This supports the shift towards fully automated laboratory workflows.

Today, Aletta® has received FDA authorization, CE mark certification in the European Union and is currently used in clinical trials in Europe. The first deployments are planned in the Netherlands, Denmark, and the United States.

Clinical Evidence

First-stick success rate of 94.5%

First-stick success rate with Aletta®

In the published results of the EU ADOPT clinical trial, the first-stick success rate was 94.5% (1)

90% of patients considers the pain less or similar to manual

considers the pain less than or similar to manual

In the published results of the EU ADOPT clinical trial, 90% of patients consider the pain less than or similar to a manual blood draw (1)

82% of patients report a preference for Aletta or has no preference going forward

report a preference for Aletta® or has no preference

In the published results of the EU ADOPT clinical trial, 82% of patients report a preference for Aletta or has no preference going forward (1)

0.6% adverse events

Mild adverse events with Aletta®

In the published results of the EU ADOPT clinical trial, mild adverse events occurred in 0.6%. No moderate or serious adverse events occurred (1)

Our clinical partners

Logo of OLVG Lab BV

OLVG Lab

OLVG Lab (Amsterdam, NL) is a clinical study site of the A.D.O.P.T. study and the first adopter of Aletta.

Logo of the St. Antonius hospital

St. Antonius

St. Antonius (Utrecht, NL) is a clinical study site of the A.D.O.P.T. study and an early adopter of Aletta.

Logo of Result laboratorium

Result Laboratorium

Result Lab (Dordrecht, NL) is a clinical study site of the A.D.O.P.T. study and an early adopter of Aletta.

Logo of Amsterdam UMC

Amsterdam UMC

Amsterdam UMC (Amsterdam, NL) is a clinical study site of the A.D.O.P.T. study and an early adopter of Aletta.

Our U.S. collaborators

We collaborate with U.S. health systems across clinical research and market research initiatives.

Our other collaborators will be added upon the health system’s internal review and approval to reference brand.

U.S. clinical research and market research collaborators

Logo of Baylor Scott & White Research Institute

Baylor Scott & White Research Institute

Clinical Research Collaborator

Logo of Mayo Clinic

Mayo Clinic Rochester

Clinic Research Collaborator

Logo of Northwestern medicine

Northwestern Medicine

Clinical Research Collaborator

Logo of Advocate Health

Advocate Health

Market Research Collaborator

BayCare

Market Research Collaborator

Logo of Intermountain Health

Intermountain Health

Market Research Collaborator

Medical University of South Carolina

Market Research Collaborator

¹ Giesen, L.F.P., Roest, J.A., et al. Performance, Safety, and Patient Experience of an Autonomous Robotic Phlebotomy Device: A Multicenter Trial. Clinical Chemistry (2026)

Note: this study evaluated an investigational version of the device. The results have not been reviewed by regulatory authorities.

staging environment
You are on the staging environment. Changes you make here do not show up on the live environment.